Releases Details
Grant of options
Released : September 10, 2020 13:42
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of options
The Options vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 8 September 2020 (being the date of Amanda's appointment), of
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Amanda Murphy |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Financial Officer |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
MaxCyte, Inc. |
|
b) |
LEI |
54930053YHXULRFCU991 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Grant of Options over Shares of Common Stock |
|
b) |
Identification Code |
US57777K1060 |
|
c) |
Nature of the transaction |
Grant of options |
|
d) |
Price(s) and volume(s) |
1,150,000 options at an exercise price of |
|
|
||
|
e) |
Aggregated information - Aggregated volume - Price |
N/A N/A N/A |
|
f) |
Date of the transaction |
8 September 2020 |
|
g) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL) and is headquartered in
For further information, please contact:
|
|
|
||||||||
|
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
